Exhibit 99.1 Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights • First patient dosing on track for first half of 2024 in clinical trial of NKX019 in lupus nephritis using disease-tailored lymphodepletion • Additional B-cell mediated autoimmune diseases under consideration for broader clinical investigation of NKX019 • Pipeline realignment focuses resources on rapid advancement of NKX019 in autoimmune diseases and deprioritizes development of NKX101 • 2023 year-end c ...